Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer

Abstract

IntroductionProstate carcinoma (PRAD) is one of the most frequently diagnosed malignancies amongst men worldwide. It is well-known that androgen receptor (AR) plays a pivotal role in a vast majority of prostate tumors. However, recent evidence emerged stating that estrogen receptors (ERs) may also contribute to prostate tumor development. Moreover, progression and aggressiveness of prostate cancer may be associated with differential expression genes of epithelial-to-mesenchymal transition (EMT). Therefore we aimed to assess the significance of receptors status as well as EMT marker genes expression among PRAD patients in accordance to their age and Gleason score.Materials and methodsWe analyzed TCGA gene expression profiles of 497 prostate tumor samples according to 43 genes involved in EMT and 3 hormone receptor genes (AR, ESR1, ESR2) as well as clinical characteristic of cancer patients. Then patients were divided into four groups according to their age and 5 groups according to Gleason score. Next, we evaluated PRAD samples according to relationship between the set of variables in different combinations and compared differential expression in subsequent groups of patients. The analysis was applied using R packages: FactoMineR, gplots, RColorBrewer and NMF.ResultsMFA analysis resulted in distinct grouping of PRAD patients into four age categories according to expression level of AR, ESR1 and ESR2 with the most distinct group of age less than 50 years old. Further investigations indicated opposite expression profiles of EMT markers between different age groups as well as strong association of EMT gene expression with Gleason score. We found that depending on age of prostate cancer patients and Gleason score EMT genes with distinctly altered expression are: KRT18, KRT19, MUC1 and COL4A1, CTNNB1, SNAI2, ZEB1 and MMP3.ConclusionsOur major observation is that prostate cancer from patients under 50 years old compared to older ones has entirely different EMT gene expression profiles showing potentially more aggressive invasive phenotype, despite Gleason score classification.

Five gene signatures were identified in the prediction of overall survival in resectable pancreatic cancer

“…[23] A heatmap was generated using the R package "gplots." [24] If not specified above, p < 0.05 was considered statistically significant.…”

The Confluence of Sex Hormones and Aging on Immunity

“…There is some evidence to indicate that tumors may also be generally less aggressive in the extremely aged ( 236 ). Indeed, breast and prostate cancer patients over the age of 55 are more likely to develop tumors with characteristics associated with favorable treatment and/or survival outcomes ( 237 , 238 ). However, it is not clear that tumors associated with other types of cancer, including bladder cancer, lung cancer, and acute myeloid leukemia, are indolent in older patients ( 239 – 242 ).…”

Could the kinetin riboside be used to inhibit human prostate cell epithelial–mesenchymal transition?

“…EMT-associated TFs, N-cadherin, and MMPs each may act in positive feedback loops activating other signalling pathways beneficial for cancer cells. It is important to note that EMT seems to be positively correlated with malignancy potential in case of PC [28]. Finally, it is noteworthy that EMT is not a binary process with many intermediate states between epithelial and mesenchymal differentiation that in fact may be most beneficial for cancer survival and development.…”